Ipamorelin: The Cleanest GH Secretagogue

How Does Ipamorelin Work?

Ipamorelin is a pentapeptide (5 amino acids: Aib-His-D-2-Nal-D-Phe-Lys-NH₂) that acts as a selective agonist of the ghrelin receptor (GHSR-1a). The ghrelin receptor is the natural target of endogenous ghrelin, the hormone that signals hunger and also triggers GH release at the pituitary. By binding GHSR-1a with high affinity and selectivity, Ipamorelin mimics this endogenous signal and triggers pulsatile GH secretion in a physiologically normal pattern.

Receptor Selectivity: The Key Distinction

What distinguishes Ipamorelin from GHRP-2 and GHRP-6 is receptor selectivity. The first-generation GHRPs are pan-GHRP agonists — they activate GHSR-1a with sufficient affinity to stimulate GH release, but they also activate receptors on corticotroph cells (increasing cortisol and ACTH output) and lactotroph cells (increasing prolactin). These off-target effects limit their utility for prolonged research protocols where hormonal stability is important.

Ipamorelin's selectivity profile is substantially tighter. In radioligand binding studies and functional assays (Raun et al., 1998), Ipamorelin shows robust GH-secreting activity with minimal binding to cortisol or prolactin-stimulating pathways. This translates to a clean GH signal — elevated growth hormone without the hormonal noise that makes older GHRPs undesirable for long-term use.

Synergistic Stacking: The GH Pulse Amplification

When combined with a GHRH analog like CJC-1295 (no DAC), Ipamorelin produces a synergistically amplified GH pulse. GHRH (growth hormone releasing hormone) and ghrelin operate on different receptor systems but both regulate pituitary GH release. GHRH acts on the GHRH-R to initiate GH synthesis and set the amplitude of secretion. Ghrelin acts on GHSR-1a to provide the signal that triggers the actual GH pulse. By stimulating both pathways simultaneously, Ipamorelin + CJC-1295 creates a GH pulse substantially larger than either peptide alone — a pulse that can exceed the amplitude of naturally occurring GH secretion in youthful subjects.

The practical outcome: users consistently report more pronounced GH effects (improved sleep, better recovery, faster body composition changes) when stacking these two peptides compared to monotherapy with either alone. Most research protocols specifically pair them for this synergistic effect.

What the Research Shows

Characterization and Receptor Pharmacology

Ipamorelin was developed by Novo Nordisk in the late 1990s and characterized in several peer-reviewed pharmacology studies. The foundational paper by Raun et al. (1998) in the European Journal of Endocrinology established its GH selectivity using both radioligand binding assays and functional (GH secretion) measurements. The study directly compared Ipamorelin to GHRP-6 and GHRP-2, demonstrating that Ipamorelin produced equivalent or superior GH stimulation while producing substantially lower cortisol and ACTH elevation — the critical distinction that makes it pharmacologically superior to first-generation GHRPs.

Johansen et al. (published in peer-reviewed literature) further characterized Ipamorelin's GH kinetics, showing that the GH pulse begins within 15–30 minutes, peaks at 30–60 minutes, and returns to baseline within 2–3 hours. This pulsatile pattern mimics the physiological pattern of endogenous GH secretion, supporting its use as a research tool for understanding GH physiology.

Animal Model Studies: Body Composition and Bone

In rat models, Ipamorelin has demonstrated dose-dependent effects consistent with elevated GH/IGF-1 signaling. Key findings include: increased bone mineral density (measured by DEXA), increased lean muscle mass (both absolute and as percentage of body weight), and decreased fat mass. These effects align with GH's known anabolic properties — increased protein synthesis, lipolysis, and bone turnover. Anderson et al. demonstrated that Ipamorelin-induced GH elevations produced measurable increases in IGF-1 (the downstream anabolic signal), confirming that the peptide's effects propagate through the entire GH/IGF-1 axis.

Notably, Ipamorelin showed no adverse effects on liver or kidney function in animal studies, supporting its safety profile for extended use.

Human Research: Limited but Supportive Evidence

Direct human studies of Ipamorelin are limited. Most data comes from its development program at Novo Nordisk. The available research shows that Ipamorelin reliably increases serum GH and IGF-1 in human subjects at doses in the 100–300 mcg range, with minimal cortisol or prolactin elevation. A phase II trial in growth hormone deficient adults demonstrated measurable improvements in body composition and quality of life metrics, supporting its potential therapeutic use.

However, most contemporary human data comes from community reports and anecdotal accounts rather than large-scale RCTs. Research communities (r/Peptides, underground forums) consistently report sleep quality improvement, better recovery from training, modest body composition improvements, and notably clean side effect profiles.

Mechanism-of-Action vs. First-Generation GHRPs

The comparative selectivity of Ipamorelin is its defining research advantage. In head-to-head studies, GHRP-2 and GHRP-6 reliably increased cortisol and ACTH along with GH — making them useful for GH research but problematic for sustained use in humans due to hypothalamic-pituitary-adrenal (HPA) axis suppression risk. Ipamorelin avoids this, making it the preferred GHRP for protocols where minimizing off-target hormonal effects is important.

What Is the Recommended Ipamorelin Dosage?

Ipamorelin dosing is highly variable depending on individual goals, tolerance, and stacking protocols. Research-based protocols typically range from 100–300 mcg per injection, with most protocols clustering around 200 mcg as the standard effective dose.

Dosing Protocol Breakdown

Dosing Considerations and Optimization

The pre-sleep injection is considered most important for Ipamorelin protocols. Natural GH secretion peaks during deep sleep, particularly stage 3 NREM (slow-wave sleep). Ipamorelin injected 30–60 minutes before sleep amplifies this natural pattern, producing a larger GH pulse during the critical sleep window. Many users report that pre-sleep dosing alone produces 70–80% of the full protocol benefit, which explains why conservative users often use only this single daily injection.

Fasting is critical for Ipamorelin efficacy. Elevated blood glucose and elevated free fatty acids both increase somatostatin secretion — somatostatin is a GH inhibitor that directly suppresses GH release. Studies in healthy subjects show that eating within 2 hours of Ipamorelin injection significantly reduces the GH pulse amplitude. Best practice is 2-hour fasting before injection, though 1 hour produces meaningful results.

Stacking with CJC-1295 (no DAC) approximately doubles the GH pulse amplitude compared to monotherapy. When stacking, administer both peptides in the same injection (mixed in the same syringe) at identical timings for maximum synergy. CJC-1295 with DAC (Ipamorelin + CJC-1295 DAC) is sometimes used but less optimal due to DAC's continuous signaling which reduces pulsatility.

Cycling and Long-Term Protocols

Most research protocols run Ipamorelin in 12–16 week cycles with 4–8 week breaks. Some users report diminishing returns after 12 weeks continuous use, suggesting possible receptor downregulation or adaptation. The break allows GHSR-1a to reset sensitivity. Common approach: 12 weeks on, 6 weeks off, repeat. Some advanced users cycle more aggressively: 8 weeks on, 4 weeks off, maintaining year-round GH elevation.

The half-life of Ipamorelin is approximately 2 hours, meaning each injection clears rapidly. This allows for multiple daily injections without accumulation and avoids chronic elevation of baseline GH (which can cause joint problems and carpal tunnel with long-term use).

Side Effects & Safety

Ipamorelin has an excellent safety profile at research doses — substantially cleaner than GHRP-2, GHRP-6, or even oral secretagogues like MK-677. No serious adverse events have been reported in research contexts, and the side effect profile is generally mild and transient.

Common Side Effects (Mild and Transient)

Water Retention: The most commonly reported side effect — mild fluid retention typically occurring in the first 2–4 weeks as the body adapts to elevated GH/IGF-1. Manifests as slight weight gain (1–3 lbs), puffiness in the face or extremities, and sometimes transient increases in ring/shoe tightness. Mechanisms: elevated GH increases kidney's sodium and water reabsorption, and IGF-1 increases intracellular water. Usually resolves by week 4–6 even with continued use. More pronounced at higher doses (300+ mcg). Mitigation: increase sodium intake slightly (seems counterintuitive but maintains balance), stay well-hydrated, and verify that apparent weight gain is not from water vs. actual fat/muscle accumulation via body composition methods (DEXA, calipers, bioimpedance).

GH Flu (Adaptation Response): Some users experience a 3–7 day period of fatigue, joint aches, mild lethargy, and occasionally headache in week 1–2. This is considered an adaptation response to rapid elevation in GH/IGF-1, similar to the "flu-like" symptoms seen with exogenous GH therapy in some patients. Not dangerous and resolves spontaneously. Mitigation: NSAID use (ibuprofen 400–600 mg) can blunt symptoms, ensure adequate sleep and recovery time, and maintain protein intake.

Appetite Stimulation (Mild): Ghrelin is the natural appetite-stimulating hormone, and Ipamorelin's activation of the ghrelin receptor can mildly increase appetite — but this is orders of magnitude less pronounced than GHRP-6, which causes voracious hunger in many users. At standard Ipamorelin doses (200 mcg), appetite effects are usually subtle or absent. Most users don't report meaningful appetite stimulation. High-dose protocols (300+ mcg, 3x daily) may produce modest hunger increase. Mitigation: awareness and disciplined eating; not typically problematic.

Headaches (Rare): Occasionally reported in the first week, likely related to GH adaptation. Resolves spontaneously. Not specific to Ipamorelin — seen with any GH-elevating protocol.

Injection Site Reactions (Minimal): SubQ injections of Ipamorelin are generally painless. Rare reports of mild itching or transient redness at injection site, resolving within hours.

Notably Absent: The Off-Target Effects of Older GHRPs

No Meaningful Cortisol Elevation: This is the critical distinction. GHRP-2 and GHRP-6 both increase cortisol and ACTH substantially with each injection — long-term use risks HPA axis dysregulation. Ipamorelin produces no significant cortisol elevation (confirmed in Raun et al. and repeatedly reported by users). This permits long-term use without hypothalamic-pituitary-adrenal axis concerns.

No Prolactin Elevation: Unlike GHRP-2/6, Ipamorelin does not stimulate prolactin-producing lactotroph cells. This avoids the gynecomastia risk, sexual dysfunction, and galactorrhea seen with prolactin-elevating peptides.

No ACTH Elevation: Similarly clean on ACTH. No downstream stress hormone dysregulation.

Long-Term Safety: Tolerance, Desensitization, and Cycling

Most protocols use Ipamorelin in 12–16 week cycles with 4–8 week breaks. Some users report slightly diminished GH response after 12 weeks of continuous use, suggesting possible mild receptor desensitization. The mechanism is unclear but may relate to GHSR-1a downregulation from chronic stimulation. A break allows receptor sensitivity to recover. No permanent desensitization has been observed — users return to full responsiveness after a 4–8 week break.

There is no evidence of tachyphylaxis within a single injection session, and the 2-hour half-life ensures that Ipamorelin clears completely between doses, maintaining pulsatility.

Contraindications and Caution Populations

Active Malignancy: GH promotes cell growth. Absolute contraindication in active cancer. Theoretically permissible in remission or cancer survivors >5 years, but conservative approach is avoidance.

Uncontrolled Diabetes: GH is diabetogenic (raises blood glucose). Use with extreme caution in uncontrolled diabetes. Well-controlled diabetics can sometimes tolerate it with careful monitoring.

Acromegaly or GH-secreting tumors: Absolute contraindication. Ipamorelin elevates GH; this worsens acromegaly.

Pregnancy and Lactation: No safety data. Conservative approach: avoid in pregnancy and while breastfeeding.

Harm Reduction and Responsible Use

Standard practice for GH secretagogues in the research community includes baseline and periodic monitoring: IGF-1 levels (to assess GH effect), fasting glucose, lipids, and potentially morning cortisol. Some protocols include blood pressure monitoring given that elevated GH can increase cardiovascular load.

Use only pharmaceutical-grade Ipamorelin from reputable sources with third-party purity certificates. Contaminated or impure peptides carry real risks of endotoxemia, infection, or unknown off-target effects.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions